Lilly Highlights Transformation Strategy for Wall Street, Reviews Robust Pipeline and Sets 2009 Financia...(Results % Growth ...)

Date:12/11/2008

Results % Growth ------------------ ------- --------- Earnings (Loss) per share ($1.56) to ($2.06) $2.71 (reported) Estimated financial impact of ImClone acquisition, including in-process research and development and other charges 4.05 to 4.50 - Charges related to Zyprexa investigations 1.33 - Asset impairments and restructuring charges (included in asset impairments, restructuring and other special charges) .25 .15 Asset impairments (included in cost of sales) .04 - In-process research and development charges associated with SGX acquisition (2008), ICOS, Hypnion, and Ivy acquisitions (2007) and in-licensing transactions with BioMS and TransPharma (2008) and OSI, MacroGenics and Glenmark (2007) .10 .63 Benefit from resolution of IRS audit (.19) - Charge for a reduction in expected insurance recoveries - .06 Pro forma as if the ICOS acquisition was completed on January 1, 2007 - (.01) -------------- --------- Earnings per share (pro forma non-GAAP) $3.97 to $4.02 $3.54 12% to 14% -------------- ---------

2009 Financial Guidance

In 2009, the company expects earnings per share of $4.00 to $4.25 on both a reported and non-GAAP basis. Excluding the estimated dilution impact of $0.30 to $0.35 per share related to the ImClone acquisition, earnings per share would be expected to be in the range of $4.35 to $4.55, reflecting growth of 8 percent to 15 percent compared to 2008 non-
'/>"/>

SOURCE Eli Lilly and Company Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Related biology technology :

1. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
2. Lilly Declares Fourth-Quarter Dividend
3. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
4. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
5. Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
6. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
7. Lilly Announces Termination of AIR Insulin Program
8. HistoRx and Lilly Extend, Expand AQUA(R) Analysis Partnership
9. Pelikan Technologies and Lilly Form Alliance to Promote Diabetes Education
10. Lilly Reports Solid First-Quarter Results
11. Lilly CEO Praises Massachusetts Leadership in Biotech, Urges Policy Prescriptions to Help Ensure States Investment Generates Dividends and Jobs